ASR Nederland

Where we land

ASR Nederland is a Dutch insurer that has spent the past few years absorbing Aegon's Dutch business, and the result is a much larger life and pensions book that now makes up 62% of its revenue. That bigger book has lifted yearly net profit to 1.1bn euros. The share price, oddly, does not seem to believe it will last: at today's level it only makes sense if earnings shrink from here. We side with the results over the price, and we award ASR a gold medal.

What the business is

Most of what ASR does is look after people's long-term money and health. Life and health insurance, which includes the pensions it runs for Dutch employers and their staff, brings in 62% of revenue. This is slow, patient business: customers pay in over decades, and the insurer earns a return on the money it holds before it pays them out.

The second pillar is commercial insurance, at 32% of revenue, covering the property, cars, liability and incomes of Dutch households and businesses. Two small lines complete the picture: managing money and giving financial advice for outside clients, at 3%, and insurance brokerage, at 2%.

After the cost of running the company, but before interest, tax and the many other claims an insurer faces, the business keeps 42% of its revenue as operating profit. For an insurer, that headline figure flatters what finally reaches shareholders.

Why now

The story of the moment is the Aegon Netherlands deal working its way into the numbers. Combining Aegon's Dutch insurance business with ASR's own brings cost savings from running one operation instead of two, a larger book of life and pension policies, and more cash flowing off that book to pay for dividends and share buybacks.

The latest evidence came on 19 August, when ASR reported a first-half profit rise of nearly 10%. Its shares have climbed hard since, among the strongest risers in the market. On growth the picture runs the other way: measured against every listed company, its standing has fallen over the past year, because the leap in sales from the merger is now behind it.

That tension is what makes this a live question. At 13 times earnings the shares sit in the middle of the range for comparable insurers, and the market is weighing a strong half-year against the sense that the easy gains from the deal have been booked.

The case for

The simplest argument for ASR is that the merger has done what it was supposed to do. Net profit of about 1.1bn in the year to June 2025 held at about 1.1bn in the year to June 2026, and the first-half rise came on top of that. After a rough patch earlier in the decade, the enlarged business has settled at a much higher, steadier level of earnings.

Sales growth has slowed sharply, from a compound 24.3% a year over three years to 6.1% in the latest year. But the three-year figure largely reflects adding Aegon's book, and nobody should expect a business to swallow a rival every year. The slowdown is less a warning than a sign the merger has been digested. What matters now is that a bigger company keeps earning at its new level, and so far it has.

The backdrop helps as well. A Dutch life insurer holds large amounts of bonds against the promises it has made, and the euro-area 10-year government bond yield has risen 0.67 points over the past year. Higher yields generally mean new money is reinvested at better returns and the capital buffer strengthens, leaving more room to pay shareholders.

Where the growth could come from

ASR is now judged on how much profit and spare cash its enlarged life and pensions book throws off. The first-half results show that engine running; the open question is whether it can keep growing, because analysts forecast earnings growth of only about 1% next year. Most of the benefit of the Aegon combination is already in the figures, so the shares lean on whether the remaining cost savings and the cash the book generates can beat that modest bar.

The next leg most likely comes from the overhaul of the Dutch pension system. As the Netherlands moves to a new regime, company and industry pension funds are being pushed to rethink how they are set up. Some may hand their existing pension promises, and the money behind them, to an insurer in what is called a buy-out; others may switch to schemes where employees build their own pots, run by providers such as ASR. Large buy-outs and new pension mandates are among the few ways a mature Dutch life insurer can add meaningfully to its book. Our figures do not separate this business within life and health, so its current size cannot be told; for now it is an option rather than the engine.

Commercial insurance is already carrying part of the results. Its profit depends on raising premiums faster than repair bills, weather damage and disability claims rise, and a few points' difference in how much of each premium goes out again can swing group profit noticeably; a bad storm season could eat into what the life side delivers. The measure to follow is the combined ratio, claims plus costs as a share of premiums, holding steady or improving while premium income grows.

The smallest option is managing money for pension funds and other institutions. It needs little capital, would add steadier fee income, and the pension reshuffle could bring it new clients. But at 3% of revenue it would take years to move group growth; rising outside assets and new institutional mandates would show it gaining ground.

The case against

The first objection is quality. Set against comparable listed insurers and financial groups, ASR's quality standing is the lowest in the group, below even the nearest name, KKR. Its 13 times earnings matches AIA and sits below MetLife and Great-West Lifeco at 19 times, but well above AXA at 9 times and China Life at 4 times. A middling price for a business at the bottom of its peers on quality is not obviously cheap.

The second is that growth has stalled even as profit rose. ASR's growth standing fell steeply over six months to below the middle of the market, with the biggest single drop on the day of the first-half results, as if investors read past the headline to what it implies. The analysts agree: their consensus sees earnings per share moving only from 6.41 to 6.48 euros.

The third is the record. In the twelve months to June 2022 the company lost 1.1bn euros at the net level, wiping out a year's worth of today's profit. In the year to June 2023 it made only 100m before recovering to 684m and then 1.1bn. A business that swung that hard so recently has not yet shown it can hold its earnings through a full turn of markets.

Finally, the operating margin of 41.9% sits beside a net margin of just 5.6%. Little of the operating figure survives to the bottom line, so modest shifts in investment results, claims or one-off charges can change what shareholders receive by a wide margin.

What the price assumes

Suppose the share price stayed flat for five years and the shares then traded at 18.5 times earnings, the middle of every profitable listed company we cover. For that to hold, ASR's earnings would need to shrink by about 6% a year, to about 4.10 euros a share in five years, well below the 6.41 analysts expect this year.

We do not set a trend against that figure. ASR's earnings have moved too unevenly, from a large loss to a thin profit to 1.1bn, to show a pattern worth carrying forward, and the merger changed the shape of the business partway through.

What the price needs is not demanding. The analysts point to slight growth, not decline, and the business has held its profit level for two years running. That is the gap behind our view: the market is pricing a slide that neither the results nor the forecasts show. Some of that scepticism has already eased, with the shares up 31% over the past year and 17% over six months.

The other side of the medal

The single risk to keep in view is that the profit lift came mostly from absorbing Aegon, while the pension handovers meant to drive what follows are still early, with little revenue yet. If so, ASR has made a large, one-time step up, and what comes next depends on a source of growth that has not yet shown up in the figures.

This goes to the heart of the gap between price and results. If the merger savings run out and the buy-outs arrive slowly or in small sizes, earnings could drift sideways for years, and a mid-range price would look less like a bargain than a fair reflection of a business that has stopped growing.

It would show itself first in the absence of news: few or no buy-out deals as Dutch funds reorganise, pension assets barely moving, and the capital the business generates each year flattening once the merger benefits are fully counted.

What to watch

The most telling signal is the spare capital the business generates each year and its solvency ratio, the capital it holds against what regulators require. If both keep rising and pay for a bigger buyback or dividend than expected, the enlarged book is proving its worth, and that would show before any change in earnings forecasts.

Alongside that, watch for signed pension buy-outs and new company pension mandates, each direct evidence of the next leg arriving well before its revenue reaches the accounts. Sales growth holding at about 6% would confirm the business is still adding to its book rather than just running it.

The case would break if net profit fell back from the 1.1bn of the last two years toward the thin or negative results of 2022 and 2023; an earlier warning would be analysts cutting the 6.41 earnings-per-share estimate. Either would mean the market's caution was right.

The numbers

The same industry, for comparison

Research for information, not personal investment advice or a recommendation to buy, sell or hold any security: see Important information. Data as at 31 October 2026.